What can cancer evolution teach us about biomarker design? 🧵 In new #TRACERx data, ORACLE🔮 ✅ prospectively associates w/ survival 🚩 predicts metastatic risk + chemo-sensitivity 🧬 encodes genetic evolution 🆕 Nature Cancer co-led by Yun-Hsin Liu with Nicolai Birkbak &

Bidirectional #mitochondria transfer swaps T cell mitochondria with those from cancer cells to impair anti-tumor immunity. Check out my News & Views in nature summarizing this incredible paper by Ikeda et al. Nature 2025 nature.com/articles/d4158…

We developed a 3-gene signature to identify tumor-specific CD8 TIL, i.e. the cells targeted by #immunotherapy, from #singlecell data. Out now in Nature Communications. All data & code are public. Please use it! #WomenInSTEM #science #research #datascience #AI nature.com/articles/s4146…

1/ JUST IN: an 8 year #kidneycancer journey now published in nature: “A personalized neoantigen vaccine generates anti-tumor immunity in high-risk renal cell carcinoma”. A trial of #RCC vaccine, led together with first author David Braun Yale Cancer Center and #PatrickOtt #DerinKeskin

📢🚨 Hot off the press The Lancet Oncology for #kidneycancer! shorturl.at/kAGVd. SABR vs thermal ablation; - Despite ⏫age, ⏬worse GFR, and ⏫tumours for SABR - SABR ⬆️effective than TA (at 1, 2 and 5 yrs) - esp for RCC >4cm - same renal decline (p=0.75) - similar F/U #radonc

I'm excited to share a new review Nature Reviews Cancer from Miriam Merad, MD, PhD lab Lipschultz Precision Immunology Institute led by X-less Chang Moon. We offer one of the most comprehensive reviews of DC functions, phenotypes, and maturation at steady-state and in cancer. It is a must-read! doi.org/10.1038/s41568…

The future of biomarkers in RCC is challenging‼️#GU25 Need for: 📊 Sample & Data Harmonisation 🔴 Overcome pervasive heterogeneity 🩸Incorporation of dynamic measures 🧠 Collaborative efforts ➡️ Generation of multimodal biomarker signatures 🧑‍💻: manifest-io.org.uk

From the March issue: NOTCH1 Drives Sexually Dimorphic Immune Responses in #HepatocellularCarcinoma brnw.ch/21wRnN4 By Katherine Lindblad Dr. Amaia Lujambio and colleagues Icahn School of Medicine at Mount Sinai The Tisch Cancer Institute

BREAKING from NEJM In cancer patients w/ Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) is : 🔘Noninferior to full-dose (5 mg BID) for VTE recurrence 🔘Lower bleeding risk (12.1% vs. 15.6%) 🔘Safer extended anticoagulation, same protection.

Actually, this does sum it up. 👍🙄

Thank you ANZUP Carole Harris Laurence E M Krieger for convening the inaugural national masterclass on #RCC. It’s only through focused, multi-disciplinary efforts that we can move efforts forward in Aus/NZ - it was a true pleasure to speak among peers! The future is bright! ✨

📢 🧬 New preprint! Can we predict which cancer patients will benefit, before treatment begins? Wan Xiang Shen Immunotherapy saves lives but many patients don’t respond to treatment, and we still lack reliable tools to predict who will benefit We introduce COMPASS, foundation

Thanks Roger Li for the shout out - & massive thanks to ANZUP for the well rounded session incorporating clinical / translational / patient voice dedicated to RCC!! 🧬🏥🗣️ chaired by Aaron Hansen & Megan Crumbaker 👍 👏👏Co-Conveners Carole Harris Laurence E M Krieger #ANZUP25

✨Such a pleasure to host Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) and Dr. Andy Wang 🇺🇦 from UTSW Peter Mac Cancer Centre today!! Your work advancing GU onc simultaneously through #clinicaltrials & translational science is inspirational! 🌟

📢 JAMA Oncol phase 2 trial: sintilimab + axitinib in advanced FH-deficient RCC (n=41) JAMA Oncology ✅ ORR 56% (4 CR, 19 PR) ✅ Median PFS 19.8 mo ✅ 12-mo OS 95% ⚠️ Safety: 95% any TRAE, 32% grade ≥3 Most common: proteinuria 63%, hyperTG 59% jamanetwork.com/journals/jamao… #kidneycancer

#ScienceSaturday ❓ Why do some patients respond better to immunotherapy? ➡️ A new study in Nature found that tumors with mutations in PPP2R1A — a gene encoding a scaffold protein in the PP2A complex — were linked to much longer survival after immune checkpoint blockade (ICB).

Thank you OncoDaily & co-chairs Rana McKay, MD, FASCO Yüksel Ürün for the chance to speak #VIRO25 🎉 I’m in winderful company of 50 leading RCC experts for this event & heartened by the global efforts to better serve our patients!! 🔬👨🏻‍🔬👩🏼‍⚕️🩺

🧬 At #VIRO2025, Dr. Lewis Au highlighted a major challenge in kidney cancer: biopsy under-sampling. 🎯 Key Insight: In clear cell RCC, less than 0.0005% of tumor volume is typically sampled - a microscopic window into a massive, heterogeneous landscape. This under-sampling can